Kyowa Kirin Co., Ltd.
https://www.kyowakirin.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kyowa Kirin Co., Ltd.
Grünenthal Bolsters US Portfolio With Buyout Of Valinor
Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.
Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar
Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.
Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor
The oncology-focused start-up announced it closed a $150m series C financing that it plans to use to advance STX-478.
Getting To Global Is A Hurdle For Cell And Gene Therapies
Only three of the 10 new therapies approved by the US FDA also have been approved in the European Union, while both of the EU gene therapy approvals followed FDA clearance, a Pink Sheet analysis shows.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Nutraceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Archimedes Pharma Ltd.
- Centus Biotherapeutics Ltd.
- Daiichi Fine Chemical Co., Ltd.
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
- Kirin Pharma Company, Limited
- Kyowa Kirin Asia Pacific Pte. Ltd.
- Kyowa Kirin Australia Pty Ltd
- Kyowa Kirin International PLC
- Kyowa Pharma Chemical Co., Ltd.
- ProStrakan Group plc
- Kyowa Kirin
- Kyowa Kirin Frontier Co., Ltd.
- Kyowa Hakko Kirin (Singapore) Pte. Ltd.
- Kyowa Hakko Kirin Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice